These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24150820)

  • 1. [Appropriate off-label prescription in practice].
    Augustin M
    Hautarzt; 2013 Oct; 64(10):728-35. PubMed ID: 24150820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Off-label use and G-BA. Legal framework for off-label use].
    Brucklacher U; Brockmeyer NH; Riedel C
    Hautarzt; 2013 Oct; 64(10):736-42. PubMed ID: 24150821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Off-label use in dermatological practice. The conflict between professional duty and legal requirements].
    Brunne V; Mertins G; Reimann G; Brockmeyer NH
    Hautarzt; 2004 Aug; 55(8):727-34. PubMed ID: 15241515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["With all suitable means". Off-label-use and public statutory employers' liability insurance].
    Skudlik C; Lindemann B; Woltjen M; Brandenburg S; John SM
    Hautarzt; 2013 Oct; 64(10):743-7. PubMed ID: 24150822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label use in dermatology in Germany: what has changed since 2004.
    Brockmeyer NH; Brucklacher U; Potthoff A; Reich-Schupke S
    J Dtsch Dermatol Ges; 2009 Nov; 7(11):938-45. PubMed ID: 19386019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
    Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
    J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Law and Practice of Off-Label Prescribing and Physician Promotion.
    Syed SA; Dixson BA; Constantino E; Regan J
    J Am Acad Psychiatry Law; 2021 Mar; 49(1):53-59. PubMed ID: 33234538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.
    França K; Litewka S
    Int J Dermatol; 2019 Jul; 58(7):788-794. PubMed ID: 30168846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Off-label therapy from the perspective of the medical insurance service].
    Grell L; Rieger M
    Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.
    Albrecht J; Adamson AS; Barbieri JS; Bennett DD; Kiracofe EA; Kourosh AS; Leslie KS; Merola JF; Nguyen J; Siegfried E; Strickland N; Olbricht S; Asgari MM;
    J Am Acad Dermatol; 2019 Feb; 80(2):577-578. PubMed ID: 30244066
    [No Abstract]   [Full Text] [Related]  

  • 12. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature.
    Lindell-Osuagwu L; Korhonen MJ; Saano S; Helin-Tanninen M; Naaranlahti T; Kokki H
    J Clin Pharm Ther; 2009 Jun; 34(3):277-87. PubMed ID: 19650250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label uses of biologic agents in dermatology: a 2006 update.
    Kerns MJ; Graves JE; Smith DI; Heffernan MP
    Semin Cutan Med Surg; 2006 Dec; 25(4):226-40. PubMed ID: 17174843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey.
    Palčevski G; Skočibušić N; Vlahović-Palčevski V
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1073-7. PubMed ID: 22307225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label dermatologic therapies. Usage, risks, and mechanisms.
    Li VW; Jaffe MP; Li WW; Haynes HA
    Arch Dermatol; 1998 Nov; 134(11):1449-54. PubMed ID: 9828883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical audit of high-cost and off-label drug use in dermatology.
    Ong N; McMeniman E; Pillans P; Soyer HP
    Australas J Dermatol; 2017 Feb; 58(1):30-34. PubMed ID: 26344939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Off-label use in oncology: an inexhaustible topic?!].
    Weissbach L; Riese J
    Urologe A; 2006 Nov; 45(11):1410, 1412-4. PubMed ID: 17043888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prescribing fictitiously approved drugs: regress threatens!].
    Walbert H
    MMW Fortschr Med; 2012 Apr; 154(6):10. PubMed ID: 22642016
    [No Abstract]   [Full Text] [Related]  

  • 20. [Off-label prescription of drugs in the statutory health insurance].
    Niederauer HH
    Gesundheitswesen; 2010 Feb; 72(2):116-9. PubMed ID: 19894208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.